ARIX BIOSCIENCE PLC — Regulatory Filings 2018

Mar 6, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7665G

Arix Bioscience Plc

06 March 2018

Arix Bioscience plc

Autolus announces confidential submission of draft registration statement for potential initial public offering in the United States

6 March 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that its Group Business Autolus Limited has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of ordinary shares in the United States. The timing and the terms of this potential initial public offering have not yet been determined and are subject to market conditions and other factors.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Investor Relations Manager

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange. For further information, please visit www.arixbioscience.com

About Autolus

Autolus is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADXGDXXGGBGIU